SCLX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SCLX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-06-02), Scilex Holding Co's Intrinsic Value: Projected FCF is $0.00. The stock price of Scilex Holding Co is $1.08. Therefore, Scilex Holding Co's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.
The historical rank and industry rank for Scilex Holding Co's Intrinsic Value: Projected FCF or its related term are showing as below:
The historical data trend for Scilex Holding Co's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scilex Holding Co Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Intrinsic Value: Projected FCF | - | - | - | - | - |
Scilex Holding Co Quarterly Data | ||||||||||||
Dec19 | Dec20 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | - | - | - | - | - |
For the Drug Manufacturers - General subindustry, Scilex Holding Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Scilex Holding Co's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Scilex Holding Co (NAS:SCLX) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Scilex Holding Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 1.08 | / | ||
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Scilex Holding Co's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Sclx Stock Acquisition Jv Llc | 10 percent owner | 960 SAN ANTONIO ROAD, PALO ALTO CA 94303 |
Jay Chun | director | C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303 |
Yue Alexander Wu | director | C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121 |
Stephen Hoi Ma | officer: Chief Financial Officer | C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303 |
Tommy G Thompson | director | 7711 CARONDELET, ST. LOUIS MO 63105 |
Tien-li Lee | director | C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303 |
Sorrento Therapeutics, Inc. | 10 percent owner | 4955 DIRECTORS PLACE, SAN DIEGO CA 92121 |
David Lemus | director | C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121 |
Dorman Followwill | director | C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121 |
Henry Ji | director, officer: Executive Chairperson | 5370 RUETTE DE MER, SAN DIEGO CA 92130 |
Jaisim Shah | director, officer: See Remarks | C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560 |
Elizabeth Czerepak | officer: See Remarks | 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070 |
Laura Hamill | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Suneel G Kaji | director | 25/28 OLD BURLINGTON STREET, LONDON X0 W1S 3AN |
Steve Myint | director | C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632 |
From GuruFocus
By sperokesalga sperokesalga • 04-26-2023
By sperokesalga sperokesalga • 06-15-2023
By PRNewswire • 08-30-2023
By Marketwired • 10-03-2023
By PRNewswire PRNewswire • 06-15-2023
By PRNewswire • 07-21-2023
By PRNewswire PRNewswire • 05-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.